Nearly half of adults who started semaglutide (Ozempic, Wegovy) for obesity management discontinued treatment within 12 months, a nationwide cohort study found.
Researchers analyzed 157,822 first-time semaglutide users without diabetes in Denmark between Dec. 1, 2022, and Nov. 1, 2024, according to the study, published Aug. 28 in JAMA Network Open. The 12-month risk of discontinuation was 49%.
Here are six things to know:
- Discontinuation increased from 13% at 3 months to 27% at 6 months and 39% at 9 months.
- The risk of discontinuation was at least 41% across all baseline characteristics studied.
- Adults ages 18-29 had a higher risk of discontinuation than those ages 45-59. Men also had a higher risk than women.
- People living in low-income municipalities had a slightly higher risk of stopping treatment than those in high-income municipalities.
- One in 4 patients who discontinued semaglutide restarted treatment within three months.
- Semaglutide costs approximately €2,200 to €3,700 ($2,500 to $4,200) per year in Denmark, depending on the dose, and is not currently reimbursed.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
